Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Blood-Derived gel help rebuild bone lost to gum disease?

NCT ID NCT07146776

Disease control Sponsor: Saglik Bilimleri Universitesi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study tests whether adding injectable platelet-rich fibrin (i-PRF) to a standard bone graft helps fill in bone defects caused by advanced gum disease. Sixteen adults with stage III periodontitis will receive either the combo treatment or the graft alone during surgery. Researchers will measure bone fill and gum attachment levels over six months to see if the i-PRF makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
injectable platelet-rich fibrin (i-PRF) mixed with bovine bone graft
What this could lead to
If it works, this could point toward a better way to repair bone defects caused by gum disease, potentially improving tooth stability.
What could go wrong
This is a very small early trial (16 people) with no blinding, so results may not be reliable or generalizable. The procedure is surgical and carries typical risks like infection or pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 16 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female patients aged 18-65 years * Patients with Stage III Periodontitis according to the AAP-EFP 2017 Periodontal Disease Classification * PPD≥5 mm (if persistent 6 weeks after initial periodontal treatment) * Intrabony defects in the interproximal region with 2 or 3 walls and a depth of at least ≥3 mm * Non-smokers (those who smoke up to 10 per day may be included) Exclusion Criteria: * Patients under 18 years of age or older than 65 years of age * Patients unable to consent * Systemic diseases that could affect the success of surgery, such as uncontrolled diabetes * Single-walled intrabony defects * Those who have taken antibiotics, anti-inflammatory or immunosuppressive drugs, or birth control pills within the three months prior to the study * Those who have received active periodontal treatment within the last six months and periodontal surgery within the last year * Smoking more than 10 cigarettes per day * Pregnancy or breastfeeding * Those taking medications that affect the gums (e.g., calcium channel blockers, phenytoin or cyclosporine) * Teeth with furcation defects * Those undergoing active orthodontic treatment * Those who are allergic to the biomaterials used in the study or prescribed medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intrabony periodontal defect are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alveolar Bone Loss periodontal disorder periodontitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intrabony periodontal defect Periodontal bone loss Periodontal defect Periodontal diseases Periodontitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sağlık Bilimleri Üniversitesi

    RECRUITING

    Istanbul, Üsküdar, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.